c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Benzer Materyaller

• Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”
  Yazar:: Kim, Sung-Hyun, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
  Yazar:: Takeuchi, Asako, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
  Yazar:: de Almeida, Maria Helena, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein
  Yazar:: Lucas, Claire M., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
  Yazar:: Lucas, Claire M., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)